ACYCLOVIR - Generic Drug Details

What are the generic sources for acyclovir and what is the scope of freedom to operate?

Acyclovir is the generic ingredient in seven branded drugs marketed by Actavis Elizabeth, Apotex, Aurobindo Pharma Usa, Cadila, Cadila Pharms Ltd, Carlsbad Technology, Chartwell Molecules, Heritage, Ivax Sub Teva Pharms, Lek Pharm, Mylan, Ranbaxy, Regcon Holdings, Roxane, Strides Pharma Intl, Teva, Teva Pharms, Watson Labs, Yiling, Pharmobedient, Alembic, Amneal, Cipla, Padagis Israel, Sun Pharma Canada, Zydus Lifesciences, Bausch, Fera Pharms Llc, Amneal Pharms, Chartwell Molecular, Chartwell Rx, Cosette, Fougera Pharms Inc, Glenmark Speclt, Macleods Pharms Ltd, Prinston Inc, Torrent, Xiromed, Actavis Mid Atlantic, Aurobindo Pharma, Hetero Labs Ltd Iii, Hikma, MSN, Novitium Pharma, Rubicon Research, Vistapharm Llc, Ligand Pharms, Carlsbad, Hetero Labs Ltd V, Square Pharms, Sun Pharm Inds Ltd, Zydus Pharms, Abbvie, Eurohlth Intl Sarl, Apothecon, Chartwell Injectable, Dr Reddys, Eugia Pharma, Fresenius Kabi Usa, Hospira, Slate Run Pharma, Teva Parenteral, and Glaxosmithkline, and is included in one hundred NDAs. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Acyclovir has forty-six patent family members in twenty-nine countries.

There are fifty-six drug master file entries for acyclovir. Sixty-one suppliers are listed for this compound. There are three tentative approvals for this compound.

Summary for ACYCLOVIR

International Patents:	46
US Patents:	3
Tradenames:	7
Applicants:	63
NDAs:	100
Drug Master File Entries:	56
Finished Product Suppliers / Packagers:	61
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	144
Patent Applications:	6,453
Drug Prices:	Drug price trends for ACYCLOVIR
Drug Sales Revenues:	Drug sales revenues for ACYCLOVIR
What excipients (inactive ingredients) are in ACYCLOVIR?	ACYCLOVIR excipients list
DailyMed Link:	ACYCLOVIR at DailyMed

See drug prices for ACYCLOVIR

See drug sales revenues for ACYCLOVIR

Recent Clinical Trials for ACYCLOVIR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Sao Paulo General Hospital	PHASE4
Fundao de Amparo Pesquisa do Estado de So Paulo	PHASE4
Columbia University	PHASE2

See all ACYCLOVIR clinical trials

Generic filers with tentative approvals for ACYCLOVIR

Applicant	Application No.	Strength	Dosage Form
		200MG	CAPSULE;ORAL
		800MG	TABLET;ORAL
		400MG	TABLET;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for ACYCLOVIR

Drug Class	Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor Herpes Zoster Virus Nucleoside Analog DNA Polymerase Inhibitor Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor
Mechanism of Action	DNA Polymerase Inhibitors

Medical Subject Heading (MeSH) Categories for ACYCLOVIR

Antiviral Agents

US Patents and Regulatory Information for ACYCLOVIR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Xiromed	ACYCLOVIR	acyclovir	OINTMENT;TOPICAL	201501-001	Jan 29, 2020	AB	RX	No	No
Pharmobedient	ZOVIRAX	acyclovir	CAPSULE;ORAL	018828-001	Jan 25, 1985		DISCN	Yes	No
Eurohlth Intl Sarl	ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE	acyclovir sodium	INJECTABLE;INJECTION	074885-002	Dec 19, 1997		DISCN	No	No
Ligand Pharms	SITAVIG	acyclovir	TABLET;BUCCAL	203791-001	Apr 12, 2013		DISCN	Yes	No			Y
Zydus Pharms	ACYCLOVIR	acyclovir	TABLET;ORAL	204314-002	Aug 19, 2014	AB	RX	No	No

Expired US Patents for ACYCLOVIR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pharmobedient	ZOVIRAX	acyclovir	CAPSULE;ORAL	018828-001	Jan 25, 1985
Bausch	ZOVIRAX	acyclovir	CREAM;TOPICAL	021478-001	Dec 30, 2002
Pharmobedient	ZOVIRAX	acyclovir	TABLET;ORAL	020089-002	Apr 30, 1991
Pharmobedient	ZOVIRAX	acyclovir	TABLET;ORAL	020089-001	Apr 30, 1991
Bausch	ZOVIRAX	acyclovir	OINTMENT;TOPICAL	018604-001	Mar 29, 1982

International Patents for ACYCLOVIR

Country	Patent Number	Title	Estimated Expiration
Mexico	2008012186	PORTADOR BIOADHESIVO MUCOSAL DE LIBERACION RETARDADA PARA EL SUMINISTRO DEL PRINCIPIO ACTIVO. (MUCOSAL BIOADHESIVE SLOW RELEASE CARRIER FOR DELIVERING ACTIVE PRINCIPLES.)
Brazil	PI0709057
Poland	1998750
Argentina	060085
Japan	2009531411

Supplementary Protection Certificates for ACYCLOVIR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0809498	10C0038	France		PRODUCT NAME: ACYCLOVIR ET HYDROCORTISONE; NAT. REGISTRATION NO/DATE: NL 36 826 20100420; FIRST REGISTRATION: SK - 2108/08467-R 20091026
0809498	SPC/GB10/012	United Kingdom		PRODUCT NAME: A COMBINATION OF ACYCLOVIR AND HYDROCORTISONE; REGISTERED: UK PL18191/0001-0001 20091112

Market Dynamics and Financial Trajectory for Acyclovir

Last updated: March 5, 2026

How is the global market for acyclovir structured?

Acyclovir, an antiviral medication developed in the 1970s, primarily treats herpes simplex virus (HSV) infections, including genital herpes, cold sores, and shingles caused by varicella-zoster virus. The drug is available in oral, topical, and intravenous formulations. It has maintained market relevance due to its efficacy and safety profile.

The drug's market spans across North America, Europe, Asia-Pacific, and Latin America. North America accounts for roughly 50% of global sales, driven by high HSV prevalence, extensive healthcare infrastructure, and developed pharmaceutical markets. Europe follows, with Asia-Pacific rapidly expanding due to increasing herpes incidence and expanding healthcare access.

Market share and competition:
Acyclovir's market share is split among branded products (e.g., Zovirax by GlaxoSmithKline) and generics. The availability of low-cost generics has suppressed price premiums, contributing to a relatively mature market with slow growth rates.

What are current sales figures and revenues?

Recent data indicates:

• Global acyclovir market revenue: approximately USD 800 million in 2022.
• Geographical distribution: North America (~USD 400 million), Europe (~USD 200 million), Asia-Pacific (~USD 150 million), other regions (~USD 50 million).

The annual compound growth rate (CAGR) from 2018 to 2022 remains modest at roughly 2.5%, influenced by patent expirations and concession of market share to generics.

How do patent scenarios influence pricing and availability?

Patents for key branded acyclovir formulations expired in the early 2000s. The expiration led to a surge in generic competition, driving prices down by approximately 30-50% across major markets within five years.

Key patent expirations:

• Zovirax saw its primary U.S. patent expire in 2003.
• Similar expirations in Europe occurred between 2002-2004.

The patent landscape continues to evolve for new formulations or delivery methods. Any recent patent filings or exclusivities directly impact market control and pricing power.

What factors are shaping future market growth?

Medical need: Rising herpes virus prevalence due to increased immunosuppression from HIV, cancer treatments, and organ transplants sustains demand.
Development of alternatives: Introduction of newer antivirals with better bioavailability (e.g., valacyclovir, famciclovir) poses competition.
Formulation innovation: Liposomal or topical delivery systems might extend lifecycle or create premium product segments.
Emerging markets: Healthcare access expansion in Asia and Latin America offers growth opportunities, albeit with price competition pressures.

Potential impacts on revenue:

• The market is expected to grow slowly, with forecasts projecting USD 900 million to USD 1 billion globally by 2030, representing a CAGR of ~2-3%.
• Market growth will be constrained by patent expiration effects and generic price erosion.

How do regulatory policies influence market dynamics?

Regulatory agencies like FDA and EMA enforce strict standards for antiviral drugs. Approval of biosimilars or interchangeable generics impacts market share. Patent litigations and exclusivity periods influence the lifecycle of branded products.

Policies promoting affordable access can increase generic penetration, pressing down prices. Conversely, regulatory delays or approval hurdles for alternative formulations or delivery systems affect innovation-driven revenue.

What are financial risks and opportunities?

Risks:

• Patent cliffs (e.g., patent expiry of Zovirax) lead to revenue declines unless offset by new formulations or indications.
• Competitive pressure from generics and newer antivirals.
• Price controls and healthcare reimbursement policies reducing profit margins.

Opportunities:

• Developing combination therapies or novel delivery systems.
• Entering emerging markets with tailored pricing strategies.
• Expanding indications (e.g., varicella-zoster virus) or pediatric uses.

Summary table of key figures and trends

Aspect	Data / Trend
Market size (2022)	USD 800 million
Geographical distribution	North America 50%, Europe 25%, Asia-Pacific 19%
Growth rate (2018-2022)	2.5% CAGR
Patent expirations	2002-2004 for key formulations
Future market size (by 2030)	USD 900 million - USD 1 billion
Main competitive drivers	Brand vs. generic pricing; formulation innovation

Key Takeaways

• Acyclovir remains a core antiviral agent with a mature but stable market.
• Patent expirations and generic entries continue to pressure prices and revenue.
• Growth prospects depend on emerging markets and formulation advancements.
• Regulatory and patent landscapes significantly influence the competitive environment.
• Slow overall growth (2-3%) expects to persist through 2030, barring major innovation or policy shifts.

FAQs

Q1: How does the patent expiration of Zovirax impact revenues?
It led to a sharp decline in branded sales due to generic competition, with prices dropping by approximately 50% in major markets.

Q2: Are there new acyclovir formulations in development?
Yes. Liposomal and topical formulations are being investigated to improve drug delivery and patient adherence.

Q3: How do emerging markets influence future growth?
They present opportunities due to rising herpes prevalence and expanding healthcare access but also pose price competition challenges.

Q4: What is the main driver of market stability?
The persistent need for antiviral treatment across various herpes-related conditions underpins steady demand.

Q5: What policy changes could affect the acyclovir market?
Introduction of price controls, approval of biosimilars, or new regulations on patent extensions could alter market dynamics.

---

References

1. Statista. (2022). Global antiviral drug market revenue. Retrieved from https://www.statista.com
2. MarketWatch. (2022). Acyclovir market forecast. https://www.marketwatch.com
3. U.S. Food and Drug Administration. (2022). Patent and exclusivity policy. https://www.fda.gov
4. World Health Organization. (2021). Herpes virus prevalence data. https://www.who.int
5. Grand View Research. (2022). Antiviral drugs market report. https://www.grandviewresearch.com